ライフサイエンスコーパス: biodistribution

1 regard to transduction efficiency and vector biodistribution.

2 ce of EVs to investigate their half-life and biodistribution.

3 short circulatory half-life and inefficient biodistribution.

4 muCi) of (18)F-FES was also used for tissue biodistribution.

5 ug plasma concentrations and improved tissue biodistribution.

6 ties and is likely to affect trafficking and biodistribution.

7 e in target tissues was confirmed by ex vivo biodistribution.

8 e were tested for maximum tolerated dose and biodistribution.

9 e apparent drug half-life and improve tissue biodistribution.

10 , T(1/2)=5.6days), allow the imaging of this biodistribution.

11 of human were calculated based on the mouse biodistribution.

12 e changes in size may alter their uptake and biodistribution.

13 r understanding their cellular targeting and biodistribution.

14 Dose calculations were based on a known biodistribution.

15 ivity on interaction with PSMA and hence the biodistribution.

16 affinity, avidity, target specificities, and biodistribution.

17 tion dose, (177)Lu-PP-F11N shows a promising biodistribution.

18 environment and the lack of data about their biodistributions.

19 tudies of the role of NP size in determining biodistribution after systemic administration.

20 Biodistribution analyses indicated that infused MSCs dis

21 A comprehensive biodistribution analysis also revealed a significantly l

22 Biodistribution analysis in mice with IPF showed prolong

23 Furthermore, following biodistribution analysis of intravenously injected nanop

24 Imaging results were confirmed by ex vivo biodistribution analysis.

25 Biodistribution and autoradiographic studies were perfor

26 marrow biopsy measurements to ascertain the biodistribution and biokinetics of the radiolabeled anti

27 proprotein processing, receptor interaction, biodistribution and biostability.

28 he tracers showed major differences in their biodistribution and blood clearance.

29 Herein, we report fundamental changes in biodistribution and brain bioavailability of macrophage-

30 nockout and wildtype rats as well as in vivo biodistribution and brain PET imaging studies in wildtyp

31 n vitro and in vivo (mice and dogs), and the biodistribution and clearance of pHLIP ICG in mice.

32 nomers can be used to manipulate the in vivo biodistribution and clearance rate of polyethylene glyco

33 e daratumumab does not bind the murine CD38, biodistribution and dose-range finding were also determi

34 In this study, we compared the human biodistribution and dosimetry for (18)F-FDG after oral a

35 Methods: The biodistribution and dosimetry of (68)Ga-Tuna-2 was asses

36 s Daratumumab does not bind the murine CD38, biodistribution and DRF were also determined using an an

37 sitive and -negative tumors were studied for biodistribution and efficacy.

38 rhDNase in the lungs and to elucidate their biodistribution and elimination pathways after intratrac

39 Biodistribution and fate studies were performed to infor

40 invasive whole-body imaging with organ-level biodistribution and fluorescence image-guided identifica

41 nti-viral activity, assessment of the drug's biodistribution and kinetics in vivo may lend insight in

42 the chirality of the G@SeNPs influences the biodistribution and kinetics.

43 tive, real-time measurement of imaging probe biodistribution and metabolism in vivo.

44 The biodistribution and microSPECT/CT imaging with 111Indium

45 Biodistribution and microSPECT/CT revealed selective upt

46 Importantly, the whole body biodistribution and organ clearance of GBCAs is poorly u

47 We evaluate the lead tracer's safety, biodistribution and pharmacokinetics in healthy human vo

48 In contrast, biodistribution and positron emission tomography demonst

49 Here, we analyze the tissue biodistribution and preliminary dosimetry of 2 members o

50 nitor chimeric antigen receptor (CAR) T-cell biodistribution and proliferation harbor the potential t

51 ase 0 imaging trial examined the (18)F-FdCyd biodistribution and radiation dosimetry in 5 human subje

52 Here we present a PET biodistribution and radiation dosimetry study of (68)Ga-

53 Here, we present a PET biodistribution and radiation dosimetry study of (68)Ga-

54 okinetic properties, such as kidney-specific biodistribution and rapid renal excretion (>80% injected

55 Biodistribution and receptor blocking studies were perfo

56 e formulation, it is possible to improve the biodistribution and safety of a given therapeutic payloa

57 nally, we determined MTP(10)-HDL's favorable biodistribution and safety profile in non-human primates

58 Biodistribution and small-animal PET imaging studies wer

59 Biodistribution and SPECT imaging were done on male nono

60 Tissue biodistribution and SPECT/CT imaging of (203)Pb-L1-(203)

61 aptation of tools to rapidly quantitate cell biodistribution and survival after delivery.

62 The biodistribution and target engagement of soticlestat was

63 The self-assembly feature enhances biodistribution and the half-life of the peptides, while

64 Biodistribution and thrombus detection was investigated

65 )Zr-antibody PET imaging to measure antibody biodistribution and tissue pharmacokinetics is well esta

66 imaging was performed to visualize (18)F-FLT biodistribution and to determine pharmacokinetics.

67 es were collected to evaluate ex vivo tracer biodistribution and to perform flow cytometric, Western

68 ts therapeutic potential was hampered by its biodistribution and toxicity to normal tissues, specific

69 e "protein corona" which alters nanoparticle biodistribution and toxicity.

70 g antibody demonstrated starkly differential biodistribution and tumor accumulation properties, with

71 ma mouse xenograft model to evaluate in vivo biodistribution and tumor cell uptake.

72 We characterize the in vivo biodistribution and tumor selectivity of (86)Y-NM600, a

73 Biodistribution and tumor targeting were assessed visual

74 r (HER3) mAb GSK2849330, we investigated the biodistribution and tumor uptake of (89)Zr-labeled GSK28

75 Normal-organ biodistribution and tumor uptake were quantified using S

76 Physiologic biodistribution and tumor uptake were semiquantitatively

77 The secondary aim was to depict the tracer biodistribution and tumor-to-background ratios (TBRs) in

78 The favourable biodistribution and tumour uptake of NCPs and the absenc

79 leading to an in-depth understanding of drug biodistribution and, in turn, shedding light on ways to

80 ors, and glycan structures influence uptake, biodistribution, and circulation time.

81 e, we evaluate the safety, pharmacokinetics, biodistribution, and dosimetry (89)Zr-trastuzumab.

82 (99m)Tc, we performed in vivo SPECT imaging, biodistribution, and fluorescence imaging on BALB/c nude

83 Furthermore, the pharmacokinetics, biodistribution, and imaging characteristics were evalua

84 Conclusion: The safety, biodistribution, and internal radiation dosimetry of (18

85 strated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET).

86 purpose of this study was to assess safety, biodistribution, and radiation dosimetry in humans for t

87 rst-in-humans study investigated the safety, biodistribution, and radiation dosimetry of a novel (18)

88 study investigated the safety, tolerability, biodistribution, and radiation dosimetry of this radioph

89 OvCa xenografts by dynamic PET/MRI, ex vivo biodistribution, and radiometabolite analysis of plasma

90 body responses and IFN-gamma production) and biodistribution (antigen and adjuvant) were evaluated in

91 (177)Lu-DOTA-PP-F11N had the same biodistribution as (177)Lu-DOTA-PP-F11; however, uptake

92 10-fold-lower injected dose with the tissue biodistribution assay.

93 ng and 2-way ANOVA for the (18)F-FFNP tissue biodistribution assay.

94 Toxicity and biodistribution assessments on repeat dosing indicated t

95 0-fold and 50-fold excess of 5D3 followed by biodistribution at 24 h to determine PSMA binding specif

96 Radiotracing revealed similar lung biodistribution at 30 minutes post-injection (79.3% +/-

97 sight into the effect of AuNP size on animal biodistribution at CT dose levels, which has not previou

98 PET imaging, biodistribution, autoradiography and immunohistochemistr

99 Results of a small-scale NP biodistribution (BD) study demonstrate that PEG-PLA/CWO/

100 o studies were conducted to characterize the biodistribution, blood circulation time, neutralizing an

101 ed by CAGE exhibited significantly different biodistribution compared to control formulations.

102 xtended the circulation time and changed the biodistribution compared to the non-liposomal radiopepti

103 binding affinity to Abeta42 and higher brain biodistribution compared with its enantiomer L3.3, givin

104 Ex vivo biodistribution corroborated the accuracy of the PET dat

105 ates that toxicity, NA binding capacity, and biodistribution could be balanced to achieve maximum the

106 dose of (225)Ac-L1 was determined using the biodistribution data and alpha-camera imaging.

107 diation dosimetry was calculated using mouse biodistribution data and blood clearance kinetics from S

108 Ex vivo biodistribution data confirmed high and persistent uptak

109 Ex vivo biodistribution data confirmed the accuracy of the PET r

110 However, in vivo biodistribution data for ADCs with PEG-DM1 have not been

111 Post SPECT biodistribution data further validated tumor-specific bi

112 Biodistribution data of (125)I-labeled ligands in human

113 ng the positron-emitting (132)La and ex vivo biodistribution data separately corroborated the accumul

114 In vivo biodistribution data showed the highest tumor uptake and

115 PET/CT images and biodistribution data were acquired at 1 h after injectio

116 Biodistribution data, tumor histology images, spheroid e

117 doses were calculated on the basis of murine biodistribution data, which were translated to a human a

118 )Pb-labeled analogs was determined using the biodistribution data.

119 Firstly, biodistribution demonstrated fast clearance of [(18)F]fl

120 ocess, involving expression level (Bmax) and biodistribution determination, a PET-specific structure-

121 opeptide in vivo, although interestingly the biodistribution did not resemble that of liposome constr

122 ctive of this study was to assess the tracer biodistribution, dosimetry and quantitative methods of (

123 e main objectives were evaluation of safety, biodistribution, dosimetry, and preliminary tumor target

124 ctive of this study was to assess the tracer biodistribution, dosimetry, and quantitative methods of

125 is first-in-humans study was to evaluate the biodistribution, dosimetry, and safety of the HER2-speci

126 his preclinical evaluation was to assess the biodistribution, dosimetry, and therapeutic efficacy of

127 Biodistribution, dosimetry, and tumor uptake were quanti

128 Blood-brain biodistribution experiments corroborated these affinity

129 Biodistribution experiments were performed after the fin

130 PET/CT imaging and biodistribution experiments were performed with KB tumor

131 tumors in vivo, as evidenced by quantitative biodistribution experiments.

132 of a label at the C terminus yields the best biodistribution features for both radiometal and radioha

133 roviding a convenient method for determining biodistribution following intravenous administration in

134 gate the effect of formulation on paclitaxel biodistribution following intravenous administration in

135 To obtain a more accurate biodistribution for GO, we (i) developed a postadministr

136 ions, it will be necessary to evaluate their biodistribution for health and safety considerations.

137 M600 tissue distributions revealed a similar biodistribution for the 2 radiotracers.

138 harmaceutical ingredient, to exhibit altered biodistribution, gene expression, and function.

139 otoxicity, controllable pharmacokinetics and biodistribution, have shown promising results for renal

140 Biodistribution in a nonhuman primate showed binding in

141 unoconjugates with (89)Zr and explored their biodistribution in athymic nude, NSG, and humanized NSG

142 licity to provide a PET ligand with improved biodistribution in comparison with previously published

143 Ex vivo tracer biodistribution in immunocompetent BALB/cOlaHsd (BALB/c)

144 Results: PET images and ex vivo biodistribution in immunocompetent mice with [(89)Zr]Zr-

145 Little is known about their biodistribution in immunocompetent settings.

146 of [(18)F]favipiravir was developed and the biodistribution in mice naive to and pre-dosed with favi

147 Biodistribution in normal organs, lymph nodes, and lesio

148 as and paragangliomas and to investigate the biodistribution in patients.

149 uated for their in vivo pharmacokinetics and biodistribution in rats.

150 ormulation with vaccine antigen, undesirable biodistribution in vital organs, or unknown long-term to

151 nm), which is likely responsible for altered biodistribution in vivo.

152 lay heightened plasma exposure, reduction in biodistribution into major organs and enhanced tumor exp

153 Conclusion: [(89)Zr]Zr-DFO-N-suc-muS110 biodistribution is dependent mainly on the T-cell-target

154 ging agents, and characterizing nanoparticle biodistribution is essential for evaluating their effica

155 Our objective was to evaluate the biodistribution, kinetics, and radiation dosimetry of (6

156 RNA from nucleases, cellular uptake, in vivo biodistribution, larval mortality and gene knockdown eff

157 e was evaluated on the basis of the expected biodistribution, lesion detection rate, and physiologic

158 vitro autoradiography, PET imaging, ex vivo biodistribution, metabolite experiments, and receptor oc

159 non-Hodgkin lymphoma (NHL) and compared the biodistribution of (11)C-MET PET/CT with that of (18)F-F

160 The biodistribution of (124)I-trametinib was significantly r

161 The biodistribution of (125)I-iodo-DPA-713 was determined un

162 The biodistribution of (131)I-GMIB-anti-HER2-VHH1 was assess

163 : No statistically significant difference in biodistribution of (177)Lu was observed between the grou

164 Methods: The biodistribution of (177)Lu-octreotate was examined in BA

165 Biodistribution of (18)F-AlF-PSMA-11 (0.26 nmol/mouse, 8

166 st-in-humans radiation dosimetry results and biodistribution of (18)F-FdCyd, administered along with

167 A favorable biodistribution of (18)F-MitoPhos in vivo was observed,

168 Methods: The biodistribution of (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-

169 Results: The biodistribution of (19)F/(177)Lu-rhPSMA-7.3 revealed fas

170 The biodistribution of (213)Bi-L1 and (225)Ac-L1 revealed sp

171 mical synthesis, cell uptake, cell kill, and biodistribution of (213)Bi-L1 and (225)Ac-L1 were evalua

172 table imaging surrogate to probe the in vivo biodistribution of (225)Ac radiotherapeutics.

173 Ex vivo biodistribution of (64)Cu-LLP2A was determined by gamma-

174 Th ex vivo biodistribution of (89)Zr-BVDFO was also determined.

175 As a proof of concept, the biodistribution of (89)Zr-Df-pembrolizumab was further i

176 Biodistribution of (99m)Tc-PSMA I&S was assessed in 10 p

177 By measuring the biodistribution of 30 nanoparticles to eight tissues sim

178 igeminal nerve, were harvested to assess the biodistribution of 800CW-BSA.

179 Additionally, the biodistribution of [(18)F]FPTMP in a nonhuman primate sh

180 Here, we compared the biodistribution of AAV2.retro with its parent serotype,

181 disposition, the pharmacokinetics (PK), and biodistribution of acetaminophen were assessed in C57Bl/

182 In vivo biodistribution of anti-CD47-QD was assessed with induct

183 rm to check the effectiveness as well as the biodistribution of ASOs for exon skipping therapy.

184 Notably, the mass-based biodistribution of Ce in the tissues did not follow the

185 the tissues did not follow the number-based biodistribution of CeO(2).

186 Additionally, we have investigated the biodistribution of CIMVs-MSCs in vivo and demonstrated t

187 tion of a fitted exponential function to the biodistribution of each respective organ.

188 In vivo imaging and ex vivo biodistribution of ER-positive, HER(2)-negative MCF-7 br

189 that yttrium-86 PET can be used to track the biodistribution of GBCAs over a two-day period.

190 athecally delivered antisense drugs, and the biodistribution of intrathecal dosed antisense drugs.

191 Biodistribution of liposome-loaded neutrophils in a huma

192 The unique pharmacology and restricted biodistribution of nanobody antagonists may provide a pa

193 escribed a prodrug strategy that directs the biodistribution of parent drug nuclear receptor modulato

194 (100 micrograms) resulted in broad bilateral biodistribution of rhBeta-Gal to critical regions of pat

195 ta-gal (100 mug) resulted in broad bilateral biodistribution of rhbeta-gal to critical regions of pat

196 ke protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to th

197 Tumor uptake and biodistribution of SN22 as a polymer-based prodrug (PEG-

198 The biodistribution of Tf-Pen liposomes demonstrated ~12 and

199 Assessments of the biodistribution of the constituent materials, complete b

200 , which predicts the tumor vs. normal tissue biodistribution of the most studied pHLIP, "wild-type pH

201 With this technology, the biodistribution of the nanocarriers can be tracked and t

202 , enabling non-invasive visualization of the biodistribution of the therapeutic agent.

203 The biodistribution of the tracer was evaluated to determine

204 The EGFR expression and biodistribution of the tracer were assessed ex vivo by i

205 Anchoring anti-ICAM changed the biodistribution of this antibody similarly, yet this for

206 Here, we examined the biodistribution of various 3DNA formulations in mice.

207 toxicity and histological alterations in key biodistribution organs.

208 (18)F-FLT biodistribution over time revealed a previously unknown

209 ole-body counts, to determine safety, tracer biodistribution, pharmacokinetics, and radiation dosimet

210 Materials and Methods Biodistribution, pharmacokinetics, and stability of CM-1

211 ) in a random crossover sequence to evaluate biodistribution, pharmacokinetics, and tumor and organ d

212 erformed three substudies to investigate the biodistribution, potential for imaging arthritis and kin

213 3-Nano were synthesized to study the in vivo biodistribution profile of the liposome and GT3 individu

214 ng (PC-3) mice revealed two compounds with a biodistribution profile superior to that of [(18)F]fluor

215 -NT(7-13) as the one with the most promising biodistribution profile, characterized by high tumor upt

216 Nanoparticle delivery also changes the biodistribution profile, resulting in increased cGAMP ac

217 ates strongly differed with respect to their biodistribution profile.

218 exhibit distinctly different circulatory and biodistribution profile.

219 C-102 has previously shown favorable in vivo biodistribution properties in mouse models of CAIX-posit

220 nation of photophysical, physiochemical, and biodistribution properties that greatly enhance bioimagi

221 I study was aimed at evaluating the safety, biodistribution, radiation dosimetry, and tumor-imaging

222 ormed in Wistar rats comprising PET imaging, biodistribution, receptor occupancy, and metabolites stu

223 The ex vivo biodistribution results validated the PET/CT studies.

224 quantification data were correlated with the biodistribution results.

225 In vivo, biodistribution revealed high uptake in the liver 2 h af

226 Mutant biodistribution revealed the importance of both surface-

227 lecules are disadvantaged by a less confined biodistribution, shorter circulatory half-life, and inab

228 Biodistribution showed fast renal clearance.

229 Pharmacokinetics and biodistribution showed that (111)In-nimotuzumab-PEG(6)-D

230 )Cu-NOTA-PEG4-cRGD2 demonstrated a favorable biodistribution, slow washout, and excellent performance

231 opic breast tumors for in vivo SPECT/MRI and biodistribution studies after injection with (177)Lu-DOT

232 scent cell and PET based in vivo imaging and biodistribution studies and demonstrated that plant deri

233 ab')(2) antigal-3 was performed, followed by biodistribution studies and immunohistochemical analysis

234 Imaging data were confirmed by tracer biodistribution studies and immunohistochemistry.

235 Biodistribution studies and in vivo small-animal PET stu

236 afted athymic BALB/c nude mice were used for biodistribution studies and small-animal SPECT/CT.

237 Biodistribution studies demonstrated that after intramus

238 Brain penetration was confirmed by biodistribution studies in C57BL6 mice, with one compoun

239 Biodistribution studies in healthy rats confirmed that b

240 Biodistribution studies in LNCaP tumor-bearing mice reve

241 thesized and evaluated by PET/CT imaging and biodistribution studies in LNCaP tumor-bearing mice.

242 177)Lu and evaluated by SPECT/CT imaging and biodistribution studies in LNCaP tumor-bearing mice.

243 In vivo biodistribution studies in mice engrafted with breast tu

244 Biodistribution studies in mice revealed that liver upta

245 sitron emission tomography (PET) imaging and biodistribution studies in multiple xenograft models and

246 Biodistribution studies in the mice showed that the conc

247 se findings highlight the need for extensive biodistribution studies of novel bispecific constructs,

248 Biodistribution studies of radiolabeled multi-triazolo-p

249 Ex vivo biodistribution studies on BALB/c mice showed higher upt

250 Pharmacokinetics and biodistribution studies revealed rapid blood clearance (

251 Ex vivo biodistribution studies revealed reversible accumulation

252 Biodistribution studies revealed significant hepatobilia

253 Biodistribution studies revealed that DDA-cLNPs remained

254 Biodistribution studies revealed that systemically admin

255 Biodistribution studies showed a specific tumoral accumu

256 Biodistribution studies showed a specific tumoral accumu

257 PET imaging and biodistribution studies showed high tumor uptake for bot

258 The in vivo biodistribution studies showed localization of fluoresce

259 PET imaging and biodistribution studies showed that the tracer (S)-5-(18

260 Ex vivo biodistribution studies validated the image-derived quan

261 Biodistribution studies were conducted on LNCaP tumor-be

262 Biodistribution studies were performed at different time

263 ro performance, small-animal PET imaging and biodistribution studies were performed on HT-1080-FAP tu

264 For PET imaging and biodistribution studies, a C4-2 tumor-bearing mouse mode

265 (111)In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry.

266 In biodistribution studies, etoposide-induced cell death in

267 In biodistribution studies, exceptionally high KB tumor upt

268 c PET scan was acquired, followed by ex vivo biodistribution studies.

269 (<=5.4% injected dose per gram of tissue) in biodistribution studies.

270 r-to-background ratios, confirmed by ex vivo biodistribution studies.

271 The biodistribution study demonstrated the AuNP accumulated

272 The biodistribution study for patients treated with (177)Lu-

273 It is noteworthy that a preliminary biodistribution study on healthy mice demonstrated the s

274 The biodistribution study showed high TBRs increasing over t

275 A biodistribution study was performed over 21 d to determi

276 Using a dual isotope biodistribution study, tumor perfusion was accessed usin

277 Biodistribution suggests successful targeting of CD8+ T-

278 n should yield images that are comparable in biodistribution to conventional clinical images acquired

279 these drugs in the blood, thus reducing drug biodistribution to the brain and other tissue.

280 m of primary brain cancer, by enhancing drug biodistribution to the tumor and avoiding systemic toxic

281 ve small-animal SPECT/CT imaging and ex vivo biodistribution to understand the in vivo behavior of PE

282 adiopharmaceutical that demonstrates similar biodistribution to urea-based PSMA-targeted agents, with

283 e model organism for therapeutic assessment, biodistribution tracking, and the controlled release of

284 e slow clearance from circulation and tissue biodistribution typical of PEGylated nanoparticles.

285 ce by small-animal PET/CT imaging and tissue biodistribution using 5.55 MBq (150 muCi) of (18)F-FES.

286 demonstrate increased vaginal absorption and biodistribution via the uterine first-pass effect.

287 Biodistribution was also evaluated in tumor-free, health

288 Biodistribution was dependent on the minibody mass admin

289 Tracer biodistribution was determined in BALB/c nude mice beari

290 jection of (68)Ga-DOTA-Siglec-9 was safe and biodistribution was favorable for testing of the tracer

291 Biodistribution was performed in vivo by SPECT-CT imagin

292 Biodistribution was performed in vivo by SPECT/CT imagin

293 Biodistribution was performed in wild-type rats at 1 hou

294 The biodistribution was studied in vivo.

295 PET/CT and biodistribution were evaluated at different times after

296 analysis, which was corroborated by ex vivo biodistribution, were used to estimate the dosimetry of

297 ns of extrapolation to pre-clinical or human biodistribution with cellular level resolution for NMs s

298 flubrobenguane showed a reproducible, stable biodistribution, with the highest SUV(max) and SUV(mean)

299 However, maps of the PpIX biodistribution within the surgical field based on eithe

300 Biodistribution without and with the protease inhibitors